clinical trial · NCT05228158
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
Eisai Co., Ltd.·—·active not recruiting·n = 145
Lymphoma, FollicularTazemetostat
brief summary
The primary purpose of the study is to investigate the safety of tazemetostat in participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation under daily clinical practice.
started
Aug 16, 2021
primary completion
Mar 31, 2028
completion
Mar 31, 2028
last updated
Jan 2, 2026
official title
A Post-marketing Observational Study of Tazemetostat on Safety in Patients With Relapsed or Refractory Follicular Lymphoma With EZH2 Gene Mutation in Japan
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol